Logical Techniques and Inhibitors Incorporating the Antidiabetic Drugs: An In Vitro Study

Abstract

In the treatment of type II diabetes, the medications dapagliflozin and saxagliptin play an active role. They are known as DPP4 and SGLT2 inhibitors, and they are exceptionally potent dipeptidyl peptidase protein 4 (DPP-4) and sodium glucose transport protein 2 (SGLT2) inhibitors as well. DPP4 and SGLT2 inhibitors prevent the reabsorption of glucose in the kidneys. Tablets are the most common form in which they are administered. A number of scientific tactics, such as UV, HPLC, LC-MS, and HPTLC processes, have been developed in order to provide assurance that dapagliflozin and saxagliptin are present in the drug dose structure and mass structure. Techniques demonstrating human plasma soundness and degradation profiling are also described for both of the medicines. These logical methods can be used for the subjective and quantitative assessment of dapagliflozin and saxagliptin, and they can also be used for its related degradants in mass definitions and natural liquids. In addition, these strategies can be used for their own purposes. The preceding review provides a depiction of the audit on logical procedures, which includes an evaluation of the anti-diabetic medications.